Baby Yusra, watched over by her mother at a hospital in Dessie, Ethiopia, got a life-threatening infection within days of her premature birth. The first antibiotics that doctors tried were no help.Abenezer Israelk/Supplied
Yusra’s tiny body was hooked up to machines twice her size as her mother clutched the side of her cot, watching her baby fight for her life. Yusra had developed severe sepsis, which meant her body had turned on itself. As her immune system attacked her vital organs, doctors tried to treat her with various antibiotics. But there was a problem: none of the drugs were working.
Yusra and her twin sister had been born two months early by C-section in Woldia, a hilly town in a region of northern Ethiopia blighted by violence between rebel and government forces. The hospital where they were delivered was still recovering from a rebel raid two years earlier that had stripped it of vital supplies. At six days old, Yusra’s sister died because she needed blood the hospital did not have.
Fearing she would lose this daughter too, Yusra’s mother had taken her on a five-hour journey, past numerous military checkpoints, to a specialist hospital in Dessie.
Sepsis, which accounts for one in three newborn deaths in Ethiopia, is a condition whereby the body overreacts to an infection. It can be stopped by tackling infections early and treating them with antibiotics. But in Yusra’s case, it wasn’t that simple.
Doctors had treated her with so-called “first-line” antibiotics – drugs that are used on infections in the first instance – but they didn’t work. As they cycled through other types of antibiotics, her condition continued to deteriorate. What’s more, the drugs were expensive. Even if the doctors did find one that could save Yusra’s life, her mother might not be able to afford it.
Yusra's mother did not want to lose her to sepsis, the cause of one out of three newborn deaths in Ethiopia.Abenezer Israelk/Supplied
A reporter from The Bureau of Investigative Journalism travelled to Ethiopia and Nigeria to bring light to stories such as Yusra’s, but hers is just one example of a growing global emergency. Increasingly, infections that would once have been straightforward to manage with a course of antibiotics are no longer responding to drugs.
In 2019, drug-resistant infections were linked to nearly five million deaths around the world – more than HIV and malaria combined. More than 20 per cent occurred in sub-Saharan Africa, where the life-saving drugs that do exist can be in short supply, incorrectly prescribed and prohibitively priced.
“It’s happening on the scale of a pandemic,” says Nicholas Feasey, a professor at the Liverpool School of Tropical Medicine. “African babies are dying in huge numbers because of this very widespread and severe illness.”
And the problem is not confined to Africa. Around the world, the rate of resistance is growing and doctors on every continent are having to contend with infections that are nearly impossible to treat.
But it’s patients like Yusra who are hit hardest.
Recent droughts in the Horn of Africa have brought more intense malnutrition, conflict and economic hardship to Ethiopians, and infectious disease follows all three. In countries where health care is fragile, drug-resistant illnesses are all the more dangerous.EDUARDO SOTERAS/AFP via Getty Images
A century of antibiotics
Antibiotics are the cornerstone of modern medicine. Without them, the risk of a deadly infection would be present every time anyone underwent routine surgery, gave birth or even scraped their knee falling over.
When Alexander Fleming discovered penicillin, the first ever antibiotic, in 1928, it ushered in a new age of medicine. Since that discovery, it has been estimated that almost 500 million lives have been saved by penicillin alone. Illnesses such as meningitis and rheumatic fever went from being commonly fatal to easily treatable.
But antibiotics are fighting a moving target. The bacteria that cause infections react to their surroundings and, if given enough chances, can “learn” ways of fending off the drugs designed to kill them. When Fleming accepted the Nobel Prize for his discovery, he issued a warning: these drugs had to be used sensibly because the bacteria they treat can become resistant.
Almost a century later, we now have more than 100 types of antibiotics. Some only kill specific bacteria, some work against a wider range. All have saved countless lives across the world. But Fleming’s warning has not been heeded.
In the past quarter century alone, there has been an almost 50-per-cent increase in the amount of antibiotics used on people around the world. Antibiotics are increasingly used by doctors as a first recourse for conditions that might not require them. Where resources are scarce, lack of access to diagnostic testing and vaccines can leave doctors with little choice. In many countries, too, certain antibiotics are available over the counter without a prescription.
This overuse of these drugs – combined with a lack of clean water, sanitation and hygiene – has driven an alarming increase in antibiotic resistance. The result is that medical progress is effectively being reversed: infections from typhoid to pneumonia are becoming less easily treated with a simple round of drugs. Increasingly, they are becoming fatal.
To treat baby Adonias, doctors at the Dessie hospital in Ethiopia had to make a fateful choice about which drug to use, since they lacked the means to test their methods first.Abenezer Israel/Supplied
Patients are fighting for survival
With only around 50 beds in total and referrals coming from across the region, the babies’ intensive-care unit in Dessie was constantly at capacity. The beeping of machines across the ward merged into a single, constant drone. In a separate room to Yusra, a mother was breastfeeding her newborn son, Adonias, who was also battling an infection.
Signs of neonatal sepsis include trouble breathing, fever, poor feeding and tiredness. After complications during his birth, Adonias was showing nearly all of them. But his local hospital didn’t have the testing facilities that would show which bacteria could be causing the infection – and therefore which antibiotics would have the best chance of treating it.
With no information to go on, they took a shot in the dark and prescribed Adonias the antibiotics most commonly used for sepsis. When days passed without them taking effect, Adonias was rushed eight hours to Dessie, his mother by his side.
But again, the hospital did not have the right testing equipment. And so, again, the doctors had to gamble. “We usually have to treat them blindly,” said Tarekegn Bitew, a neonatal doctor in Dessie’s intensive-care unit. “If they don’t improve with the first-line antibiotics, we suspect clinical drug resistance and blindly prescribe second-line antibiotics.”
Prescribing blind is a regular part of the job for doctors like Dr. Terekegn, not least because hospitals can be a hotbed for infections. The high concentration of sick people and presence of antibiotics can lead to bacteria surviving, getting stronger and spreading between patients. And if the wrong antibiotics are prescribed by doctors going on guesswork, the bacteria will continue to multiply, and the patient’s condition worsens.
In Adonias’s case, the second-line antibiotics seemed to be working. He was feeding more regularly and required less oxygen. But without testing there was no way to be certain.
A nurse attends to a nine-day-old baby at Massey Children's Hospital. Born at 26 weeks old, the baby got Cefotaxime antibiotics, but those didn't work when the regimen was over, so meropenem was tried instead.Damilola Onafuwa
Another premature patient at Massey, Enyioha, was left behind by her family as she struggled with drug-resistant neonatal sepsis.Damilola Onafuwa/Supplied
Testing times
On the other side of the continent, in a neonatal ward in Lagos, lay Eniyoha, a weeks-old baby who had been abandoned by her parents at a hospital.
The hospital was in the midst of one of the power blackouts that plague the Nigerian city. And with the ward quickly losing daylight, the nurses prepared to do what they could to keep the babies warm.
The erratic power supply meant also that the patients’ medical records had to be kept on paper. Eniyoha’s file was already thick with notes detailing her condition, complications and treatments. She had been born eight weeks early with birth defects that meant lifelong physical impairments. Her parents had left her without an explanation, but hospital staff said it was likely that they couldn’t afford the hospital bill.
Eniyoha also had drug-resistant neonatal sepsis. Almost all of the babies admitted at the hospital in Lagos are septic before they arrive.
With resources limited, the staff were doing what they could. For more than a year, they had swabbed the ward every day for bacteria and sent the samples for testing in government labs. The results were compiled and used to try and decide which drugs to use to treat the sick babies.
While the hospital didn’t have the means to test every baby for infection, it now had a cheat sheet: a list of antibiotics with a higher chance of success in treating these infections. This removed some of the guesswork, saving valuable time in the race to save lives.
This has never been more urgent. In Nigeria, one in every 29 babies die within four weeks of being born. Sepsis is one of the main causes. For premature babies such as Yusra and Eniyoha, the odds of surviving from a drug-resistant infection are even lower.
A woman navigates the garbage-strewn passageways of Makoko, a floating slum in Lagos. Nigerians who get sick from these waters have few options for affordable care, since hospitals do not pay for antibiotics.Sunday Alamba/The Associated Press
Counting costs
Eniyoha’s infection had not responded to either first or second-line antibiotics, so doctors were trying a third type. But in Nigeria, hospitals do not cover the costs of any drugs, and so for now, money from hospital donors was being used to foot the bill.
“It’s out of pocket,” said Folakemi Irewole-Ojo, medical director of the hospital, referring to the costs faced by patients needing antibiotics. “We come across parents that can’t afford treatment every day.”
“It’s the long duration of treatment – by the time the preterm babies have spent two weeks here, [the parent’s] pocket is dry.”
For premature babies, hospital stays can last for weeks. And the bills rack up.
The concern was echoed by doctors in Ethiopia, where hospitals cover the costs of some drugs but not others. “The cost is also high, we don’t know which patient will be sensitive to which antibiotics,” Dr. Tarekegn said.
The standard approach, then, is to try the cheaper ones first. But if these fail, and a baby needs to be put onto so-called “last-resort” antibiotics such as meropenem, then the costs fall outside of the hospital’s budget. And a full course of treatment – around 20 vials – can cost five times as much as an average person earns in an entire month.
“If we had testing in this hospital, we would be able to improve patient management,” Dr. Tarekegn said. “It would also decrease the costs for the families.”
At times, in hopes of spreading costs and saving money, vials of medicine and other hospital equipment are shared among patients. This is especially common among babies as they require smaller doses of medication than adults – and sometimes a single vial of meropenem is shared between three babies. Though it makes the most of scant resources, it can mean infections spread more easily across wards.
“Having to share hospital equipment is a major source of drug-resistant infections among neonates,” says Jonathan Strysko, a pediatrician and infectious disease epidemiologist based in Botswana. “It’s the fact hospitals have major reservoirs [of bacteria], like equipment that can never be fully cleaned.”
If not properly sanitized, the equipment is at risk of contamination by the bacteria that cause these fatal infections. “We need different ways of looking at infection prevention and controls in the hospital setting,” Dr. Strysko said. There is an added difficulty if hospitals do not have access to clean water.
In the neonatal ward in Lagos, the doctors’ cheat sheet had done its job: Eniyoha’s infection cleared. Social services are now trying to trace her parents. Back in Dessie, Adonias also continued to improve and was soon discharged from hospital.
Yusra, though, had not responded to second-line antibiotics. As her daughter’s health deteriorated, Yusra’s mother tried to get hold of meropenem before it was too late. It was on sale at pharmacies just outside of the hospital gates, but she didn’t have the money to pay for it. Her daughter died five days later.
A child looks out at school grounds, used as shelter, at a camp for internally displaced people in Mekelle, Tigray. Here, many of those uprooted by Ethiopia's two-year civil war are still in dire need. The winding-down of humanitarian programs has left the poorest people at greater risk of health problems like the ones that sent Yusra and her mother to Dessie.MICHELE SPATARI/AFP via Getty Images
Lives on the line
Although The Bureau of Investigative Journalism spent just a short time in the hospital in Dessie, half the babies the reporter was introduced to did not survive more than the first few weeks of their lives. It’s something these doctors and nurses witness time and time again.
“Most of the patients die,” said Dr. Bitew, the neonatal doctor. “Some of them do improve.”
And while the babies in his ward are among those worst affected by drug-resistant infections, they are far from the only ones put at risk by an increasingly global problem.
As more and more bacteria learn how to fend off human medicine, we are all at risk of dying from infections that are becoming untreatable. But for now, it’s the most helpless patients who find themselves on the front lines.
Their access to testing equipment, vaccinations, clean water, sanitation and hygiene must all be addressed. As Dr. Feasey, the tropical medicine professor, said: “A holistic approach needs to be taken to prevent neonatal sepsis and to get those extremely vulnerable babies through the first 30 days of their life.”
Without it, he says, “the frailest members of African society will continue to die.”
This story was produced by The Bureau of Investigative Journalism with reporting by Misbah Khan. TBIJ is funded by the British Society for Antimicrobial Chemotherapy.
Global health: More from The Globe and Mail
The Decibel podcast
Wastewater monitoring and genetic sequencing have given the world’s researchers a clearer idea of how COVID-19 variants mutate and spread. So why is Ontario shutting its program down? Science reporter Ivan Semeniuk joined The Decibel to explain why experts are worried. Subscribe for more episodes.
Infectious disease in depth
André Picard: The world is making steady progress tackling HIV-AIDS – but challenges remain
Health agencies rolling out new ‘breakthrough’ malaria vaccine in Africa
TB and intense heat are a deadly mix in the Philippines’s crowded jails